Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelabresib extension study
NL-OMON59938Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of pelabresib in myelofibrosis (MF), thrombocythemia and myeloproliferative disorder (MPD), sponsored by Novartis. Started Nov 2024; status: recruiting.
02
Drugs
pelabresib
03
Conditions
myelofibrosis (MF)thrombocythemiamyeloproliferative disorder (MPD)
Beyond the preview
Go deeper on NL-OMON59938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59938.